✦ LIBER ✦

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

✍ Scribed by Gopal, Ajay K.; Kahl, Brad S.; de Vos, Sven; Wagner-Johnston, Nina D.; Schuster, Stephen J.; Jurczak, Wojciech J.; Flinn, Ian W.; Flowers, Christopher R.; Martin, Peter; Viardot, Andreas; Blum, Kristie A.; Goy, Andre H.; Davies, Andrew J.; Zinzani, Pier Luigi; Dreyling, Martin; Johnson, Dave; Miller, Langdon L.; Holes, Leanne; Li, Daniel; Dansey, Roger D.; Godfrey, Wayne R.; Salles, Gilles A.

Book ID: 121720909
Publisher: Massachusetts Medical Society
Year: 2014
Tongue: English
Weight: 674 KB
Volume: 370
Category: Article
ISSN: 0096-6762
DOI: 10.1056/nejmoa1314583

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1 study of the PI3K inhibitor id

A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

✍ Kahl, B. S.; Spurgeon, S. E.; Furman, R. R.; Flinn, I. W.; Coutre, S. E.; Brown, 📂 Article 📅 2014 🏛 American Society of Hematology 🌐 English ⚖ 561 KB

Japanese phase II study of 90Y-ibritumom

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

✍ Kensei Tobinai; Takashi Watanabe; Michinori Ogura; Yasuo Morishima; Tomomitsu Ho 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Obinutuzumab (GA101) in Patients With Re

Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study

✍ Salles, G. A.; Morschhauser, F.; Solal-Celigny, P.; Thieblemont, C.; Lamy, T.; T 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 153 KB

Lenalidomide plus rituximab can produce

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma

✍ Tuscano, Joseph M.; Dutia, Mrinal; Chee, Karen; Brunson, Ann; Reed-Pease, Christ 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

A phase II study of Xcellerated T cells™

A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL)

✍ J.G. Gribben; N.L. Bartlett; J.J. Stephenson; M.S. Milder; R.V. Boccia; C. Redfe 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB